source
- Kailera's oral GLP-1 pill shows ~10% weight loss in Chinese Phase 3 trialKailera Therapeutics reported that its oral GLP-1 candidate HRS-7535 achieved about 10% average weight loss over 44 weeks in a Phase 3 study in China. The highest daily dose led to a mean 9.8% red…
- Novartis to buy Myricx Bio for up to $1.5 billion, adding two novel ADCs to its oncology portfolioNovartis announced it will acquire Myricx Bio, a UK‑based biotech that develops antibody drug conjugates (ADCs), in a move to broaden its oncology pipeline. The transaction is valued at up to $1.5…